Bullish Moving Averages
15
Bearish Moving Averages
1
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
986.80Today’s High
1010.7052W low
542.4052W High
1094.00Open Price
1002.50Prev. Close
927.0000Volume
278160.00Value
275447940.00Fundamentals
Market Cap Cr
19464.70
Price to Earnings
33.00
Price to Book Value
4.50
Dividend Yield
0.80
PE to Growth
0.20
Op Revenue TTM Cr
6118.10
Net Profit TTM Cr
590.21
Cash From Operating Activity Cr
723.95
Return on Equity %
7.82
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
26 Apr, 2024
82.4
Week
60.2
Month
53.4
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
995.90
PIVOT
First Resistance
1005.05
Second Resistance
1019.85
Third Resistance
1029.00
First Support
981.10
Second Support
971.95
Third Support
957.15
Relative Strength Index
53.98
Money Flow Index
57.95
MACD
-3.48
MACD Signal
-4.74
Average True Range
33.58
Average Directional Index
17.28
Rate of Change (21)
3.43
Rate of Change (125)
30.48
Commodity Channel Index
46.5
Williams %R
-43.5
BETA
1 Month
1.72
3 Month
1.73
1 Year
0.57
3 Year
0.19
PRICE CHANGE ANALYSIS
↑ 5.53%
1 Week
Low
High
933.5
1010.7
↑ 2.35%
1 Month
Low
High
913.95
1049
↑ 5.16%
3 Months
Low
High
892
1094
↑ 32.61%
6 Months
Low
High
707.15
1094
↑ 80.5%
1 Year
Low
High
542.4
1094
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 1591.69 | 1487.80 | 1344.12 | 1309.08 | 1310.79 | 1354.89 | 1160.95 | 1315.91 | 1234.25 | 1191.48 | 1271.43 | |
| Operating Expenses Qtr | 1251.25 | 1271.38 | 1166.54 | 1137.94 | 1085.98 | 1109.13 | 1033.70 | 1013.01 | 950.08 | 952.82 | 992.72 | |
| Operating Profit Qtr | 337.14 | 207.46 | 165.73 | 169.18 | 224.23 | 245.29 | 126.63 | 291.30 | 282.75 | 236.95 | 276.97 | |
| EBIDT Qtr Cr | 340.44 | 216.41 | 177.57 | 171.14 | 224.81 | 245.76 | 127.25 | 302.90 | 284.16 | 238.66 | 278.71 | |
| Depreciation Qtr | 69.08 | 67.18 | 65.75 | 73.54 | 65.85 | 66.80 | 46.09 | 45.95 | 45.34 | 44.53 | 43.49 | |
| Net Profit Qtr | 233.24 | 133.84 | 97.53 | 130.54 | 119.13 | 146.44 | 72.46 | 251.37 | 193.58 | 156.35 | 192.69 | |
| Basic EPS Qtr | 11.87 | 6.81 | 4.96 | 6.64 | 6.06 | 7.45 | 3.69 | 12.79 | 9.85 | 7.95 | 9.80 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 5152.54 | 5086.55 | 5061.17 | 4267.30 | 3666.69 | |
| Operating Expenses Annual Cr | 4484.65 | 4126.61 | 3479.21 | 2929.65 | 2781.60 | |
| Operating Profit Annual | 664.35 | 908.80 | 1572.23 | 1202.90 | 878.67 | |
| Operating Profit Margin Annual % | 12.89 | 17.87 | 31.06 | 28.19 | 23.96 | |
| Total Expenses Annual Cr | 4806.60 | 4428.55 | 3644.58 | 3090.51 | 2902.06 | |
| EBIDT Annual Cr | 667.89 | 959.94 | 1581.96 | 1337.65 | 885.09 | |
| EBIDT Annual margin % | 12.96 | 18.87 | 31.26 | 31.35 | 24.14 | |
| Depreciation | 272.95 | 284.92 | 152.60 | 135.67 | 105.59 | |
| PAT Before ExtraOrdinary Items Annual Cr | 346.73 | 543.55 | 1175.39 | 969.40 | 611.21 | |
| Net Profit Annual | 346.73 | 543.55 | 1175.39 | 969.40 | 611.21 | |
| Basic EPS Annual | 17.64 | 27.65 | 60.67 | 51.42 | 32.42 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 4414.29 | 5290.34 | 5254.24 | 3346.02 | 2712.41 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 164.83 | 204.25 | 398.47 | 1079.26 | 595.90 | |
| Total Current Liabilities Annual Cr | 1551.30 | 1579.45 | 1123.47 | 1453.49 | 1240.72 | |
| Total Capital Plus Liabilities Annual Cr | 6130.42 | 7074.04 | 6776.18 | 5878.77 | 4549.03 | |
| Fixed Assets Annual | 2978.73 | 4075.33 | 3388.81 | 2846.44 | 2192.32 | |
| Total Non Current Assets Annual | 3350.20 | 4329.58 | 4402.23 | 3727.40 | 2713.02 | |
| Total Current Assets Annual | 2780.22 | 2744.46 | 2373.95 | 2151.37 | 1836.01 | |
| Total Assets Annual | 6130.42 | 7074.04 | 6776.18 | 5878.77 | 4549.03 | |
| Contingent Liabilities plus Commitments Annual Cr | 326.18 | 228.15 | 327.06 | 455.59 | 409.05 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 730.25 | 545.26 | 1485.30 | 539.75 | 808.80 | |
| Cash from Investing Activity Annual | -460.98 | -368.72 | -925.55 | -822.31 | -753.59 | |
| Cash from Financing Annual Activity | -261.16 | -216.64 | -533.60 | 166.13 | 79.67 | |
| Net Cash Flow Annual | 8.11 | -40.10 | 26.15 | -116.43 | 134.88 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 224.59 | 269.16 | 267.32 | 177.51 | 143.89 | |
| ROE Annual % | 7.85 | 10.27 | 22.37 | 28.97 | 22.53 | |
| ROCE Annual % | 8.62 | 12.28 | 25.28 | 27.16 | 23.56 | |
| Total Debt to Total Equity Annual | 0.14 | 0.12 | 0.04 | 0.50 | 0.32 | |
| EBDIT Annual Margin % | 12.97 | 19.06 | 31.31 | 32.36 | 24.18 |
| Indicator | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 1633.46 | 1605.09 | 1497.81 | 1407.34 | 1509.46 | 1475.34 | 1263.22 | 1426.01 | 1273.04 | 1294.52 | 1327.91 | |
| Operating Expenses Qtr | 1364.21 | 1386.69 | 1287.46 | 1194.23 | 1260.27 | 1242.27 | 1247.49 | 1255.63 | 1016.05 | 1035.09 | 1090.10 | |
| Operating Profit Qtr | 266.36 | 208.25 | 198.69 | 212.22 | 248.75 | 232.74 | 14.65 | 160.11 | 255.65 | 257.23 | 235.93 | |
| EBIDT Qtr Cr | 269.25 | 218.40 | 210.35 | 213.11 | 249.19 | 233.07 | 15.73 | 170.38 | 257.00 | 259.43 | 237.81 | |
| Depreciation Qtr | 69.45 | 67.56 | 66.18 | 74.12 | 66.51 | 67.70 | 67.10 | 123.08 | 55.94 | 54.60 | 53.15 | |
| Net Profit Qtr | 180.45 | 136.56 | 120.60 | 152.60 | 121.92 | 133.35 | -65.88 | 35.46 | 176.42 | 169.29 | 158.27 | |
| Basic EPS Qtr | 9.18 | 6.95 | 6.14 | 7.76 | 6.20 | 6.78 | -3.35 | 1.80 | 8.98 | 8.61 | 8.37 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 5655.36 | 5356.25 | 5403.15 | 4610.69 | 3944.06 | |
| Operating Expenses Annual Cr | 4944.24 | 4431.63 | 3835.58 | 3382.73 | 3061.10 | |
| Operating Profit Annual | 708.38 | 874.16 | 1557.55 | 1223.02 | 873.58 | |
| Operating Profit Margin Annual % | 12.53 | 16.32 | 28.83 | 26.53 | 22.15 | |
| Total Expenses Annual Cr | 5269.84 | 4736.14 | 4035.07 | 3567.21 | 3194.74 | |
| EBIDT Annual Cr | 711.12 | 924.62 | 1567.57 | 1227.96 | 882.96 | |
| EBIDT Annual margin % | 12.57 | 17.26 | 29.01 | 26.63 | 22.39 | |
| Depreciation | 275.43 | 286.78 | 183.47 | 157.32 | 115.23 | |
| PAT Before ExtraOrdinary Items Annual Cr | 372.91 | 515.65 | 1114.76 | 800.65 | 592.57 | |
| Net Profit Annual | 341.99 | 520.94 | 1178.11 | 828.82 | 584.37 | |
| Basic EPS Annual | 17.40 | 26.50 | 60.81 | 43.97 | 31.00 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 4370.47 | 5237.54 | 5127.61 | 3219.41 | 2718.83 | |
| Minority Interest Liability Annual Cr | 0.00 | 0.00 | -60.64 | -28.96 | -0.79 | |
| Total Non Current Liabilities Annual Cr | 175.43 | 167.96 | 361.16 | 1046.99 | 570.07 | |
| Total Current Liabilities Annual Cr | 1636.93 | 1716.53 | 1280.85 | 1751.60 | 1489.68 | |
| Total Capital Plus Liabilities Annual Cr | 6182.83 | 7122.03 | 6708.98 | 5989.04 | 4777.79 | |
| Fixed Assets Annual | 2999.73 | 4102.08 | 3970.96 | 3398.02 | 2706.07 | |
| Total Non Current Assets Annual | 3272.81 | 4261.24 | 4131.08 | 3526.30 | 2820.03 | |
| Total Current Assets Annual | 2910.02 | 2860.79 | 2577.90 | 2462.74 | 1957.76 | |
| Total Assets Annual | 6182.83 | 7122.03 | 6708.98 | 5989.04 | 4777.79 | |
| Contingent Liabilities plus Commitments Annual Cr | 317.96 | 228.15 | 349.23 | 386.98 | 260.88 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 723.95 | 552.36 | 1463.38 | 449.13 | 811.96 | |
| Cash from Investing Activity Annual | -447.59 | -371.97 | -838.81 | -731.63 | -755.60 | |
| Cash from Financing Annual Activity | -261.96 | -217.36 | -597.42 | 154.86 | 59.04 | |
| Net Cash Flow Annual | 14.40 | -36.97 | 27.15 | -127.64 | 115.40 |
| Indicator | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 222.36 | 266.47 | 257.80 | 169.25 | 144.19 | |
| ROE Annual % | 7.82 | 9.94 | 22.97 | 25.74 | 21.49 | |
| ROCE Annual % | 9.58 | 11.79 | 25.49 | 25.26 | 23.34 | |
| Total Debt to Total Equity Annual | 0.15 | 0.12 | 0.04 | 0.54 | 0.34 | |
| EBDIT Annual Margin % | 12.58 | 17.42 | 29.06 | 26.66 | 22.44 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Kotak Small Cap Fund | 1.76 | 74393548 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Chirayu Ramanbhai Amin | 2.13 | 74393510 | 0 | 0 |
| Malika Chirayu Amin | 1.53 | 74393511 | 0 | 0 |
| Pranav Chirayu Amin | 0.51 | 74393512 | 0 | 0 |
| Shaunak Chirayu Amin | 0.51 | 74393513 | 0 | 0 |
| Nirayu Limited | 35.63 | 74393521 | 0 | 0 |
| Alembic Limited | 28.54 | 74393522 | 0 | 0 |
| Udit Chirayu Amin | 0.51 | 74393543 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| DSP Midcap Fund | 3.92 | 74393547 |
| Kotak Small Cap Fund | 1.76 | 74393548 |
| Life Insurance Corporation Of India | 4.33 | 74393550 |
| Name | Holding Percent | Holding Id |
|---|
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 28, 2023 | 8 | FINAL | Jul 28, 2023 | Equity Share |
| Aug 17, 2022 | 10 | INTERIM | Aug 18, 2022 | Equity Share |
| Jul 19, 2021 | 14 | FINAL | - | Equity Share |
| Mar 16, 2020 | 7 | INTERIM | Mar 17, 2020 | Equity Share |
| Mar 16, 2020 | 3 | SPECIAL | Mar 17, 2020 | Equity Share |
| Jul 18, 2019 | 5.5 | FINAL | - | Equity Share |
| Jul 18, 2018 | 4 | FINAL | - | Equity Share |
| Jul 11, 2017 | 4 | FINAL | - | Equity Share |
| Jul 20, 2016 | 4 | FINAL | - | Equity Share |
| Jul 22, 2015 | 3.5 | FINAL | - | Equity Share |
| Jul 17, 2014 | 3 | FINAL | - | Equity Share |
| Jul 29, 2013 | 2.5 | FINAL | - | Equity Share |
| Jul 31, 2012 | 1.4 | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 09, 2024 | Audited Results & Final Dividend | - |
| Feb 05, 2024 | Quarterly Results | - |
| Nov 07, 2023 | Quarterly Results | - |
| Aug 04, 2023 | Quarterly Results | - |
| May 05, 2023 | Audited Results & Final Dividend | - |
| Feb 01, 2023 | Quarterly Results | - |
| Nov 11, 2022 | Quarterly Results | - |
| Aug 04, 2022 | Quarterly Results & Others | To change dividend type from Final Dividend to Interim Dividend |
| May 02, 2022 | Audited Results & Dividend | - |
| Feb 10, 2022 | Quarterly Results | - |
| Nov 10, 2021 | Quarterly Results | - |
| Jul 26, 2021 | Quarterly Results | - |
| May 04, 2021 | Audited Results & Dividend | - |
| Jan 19, 2021 | Quarterly Results | - |
| Oct 22, 2020 | Quarterly Results | - |
| Aug 06, 2020 | To consider raising of funds | - |
| Jul 27, 2020 | Others | Inter alia to consider fund raising by way of a qualified institutions placement. |
| Jul 22, 2020 | Quarterly Results | - |
| May 22, 2020 | Audited Results | - |
| Apr 23, 2020 | Quarterly Results | - |
| Mar 06, 2020 | Interim Dividend | - |
| Jan 22, 2020 | Quarterly Results | - |
| Oct 24, 2019 | Quarterly Results | - |
| Jul 29, 2019 | Quarterly Results | - |
| Jun 12, 2019 | Others | inter alia, to consider and approve the proposal for issue of NonConvertible Debentures on Private Placement Basis. |
| May 08, 2019 | Audited Results & Dividend | - |
| Jan 22, 2019 | Quarterly Results | - |
| Dec 14, 2018 | Others | To consider and approve the issue and allotment of Unsecured Redeemable Non-Convertible Debentures (NCDs) of upto Rs. 350 Crores on Private Placement Basis. |
| Dec 06, 2018 | Others | To consider and approve a fresh proposal for issue of Non-Convertible Debentures on Private Placement Basis, superceding the earlier resolution. |
| Oct 22, 2018 | Quarterly Results | - |
| Sep 10, 2018 | Others | To consider the proposal for issue of Non-Convertible Debentures on Private Placement Basis. |
| Jul 27, 2018 | Quarterly Results | - |
| May 16, 2018 | Audited Results & Dividend | - |
| Jan 31, 2018 | Quarterly Results | - |
| Nov 07, 2017 | Quarterly Results | - |
| Jul 20, 2017 | Quarterly Results | - |
| May 03, 2017 | Audited Results & Dividend | - |
| Jan 25, 2017 | Quarterly Results | - |
| Oct 25, 2016 | Quarterly Results | - |
| Jul 29, 2016 | Quarterly Results | - |
| Apr 27, 2016 | Audited Results & Dividend | - |
| Jan 21, 2016 | Quarterly Results | - |
| Oct 27, 2015 | Quarterly Results | - |
| Jul 31, 2015 | Quarterly Results | - |
| Apr 27, 2015 | Audited Results & Dividend | Appointed Mr. Pranav Amin as Joint Managing Director w.e.f. April 27, 2015. |
| Feb 04, 2015 | Quarterly Results | - |
| Oct 20, 2014 | Quarterly Results | - |
| Jul 28, 2014 | Quarterly Results | - |
| Apr 28, 2014 | Audited Results & Dividend | - |
| Jan 22, 2014 | Quarterly Results | - |
| Oct 25, 2013 | Quarterly Results | (Revised) |
| Aug 07, 2013 | Quarterly Results | - |
| May 02, 2013 | Audited Results & Dividend | - |
| Jan 21, 2013 | Quarterly Results | - |
| Oct 19, 2012 | Quarterly Results | - |
| Aug 09, 2012 | Quarterly Results | - |
| Apr 25, 2012 | Audited Results & Dividend | - |
| Feb 08, 2012 | Quarterly Results | - |
| Oct 19, 2011 | Quarterly Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
26 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Under Regulation 30
Please find attached herewith the Intimation under Regulation 30 of SEBI LODR, Regulations 2015.
25 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement Under Regulation 30 Of SEBI LODR
Kindly find attached herewith the Announcement under Regulation 30 of SEBI regulations, 2015.
25 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the Intimation dated 25th April, 2024 received from our RTA.
23 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find attached herewith a copy of newspaper advertisement related to Notice of claiming shares from Company''s Unclaimed Suspense Account published in English language newspaper - Business Standard on 23rd April, 2024.
19 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company ALEMBIC PHARMACEUTICALS LTD. 2 CIN NO. L24230GJ2010PLC061123 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2023-24, 2024-25 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) Not Applicable 8Quantum of (d), which has been met from (c)(e)* Not Applicable 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* Not Applicable Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2022-23, 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Manisha SarafDesignation :-Company Secretary Name of the Chief Financial Officer :- Rajkumar Baheti Designation : -Director Finance and CFO Date: 19/04/2024
19 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyALEMBIC PHARMACEUTICALS LTD. 2CIN NO.L24230GJ2010PLC061123 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manisha Saraf Designation: Company Secretary EmailId: apl.investors@alembic.co.in Name of the Chief Financial Officer: Rajkumar Baheti Designation: Director Finance and CFO EmailId: medha@alembic.co.in Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
19 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find attached herewith the Intimation dated 19th April, 2024 received from out RTA.
18 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on Thursday, 9th May, 2024 as per the enclosed details.
18 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Intimation for To Consider The Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2024
ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 ,inter alia, to consider and approve 1. Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2024. 2. Dividend on equity shares, if any, for the financial year ended 31st March, 2024. Pursuant to the Company''s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives, the trading window for dealing in securities of the Company which was closed from 1st April, 2024, will re-open 48 hours after the declaration of the financial results
15 Apr 2024
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2024
Please find attached herewith the Certificate under Regulation 40(9) of SEBI LODR Regulations, 2015 for the Financial Year ended on 31st March, 2024 received from M/s. Samdani Shah & Kabra, Practicing Company Secretaries.
